<DOC>
	<DOCNO>NCT00003691</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy consist doxorubicin cisplatin without paclitaxel G-CSF treating patient stage III , stage IV , recurrent endometrial cancer .</brief_summary>
	<brief_title>Combination Chemotherapy With Without G-CSF Treating Patients With Stage III , Stage IV , Recurrent Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether addition paclitaxel , use filgrastim ( G-CSF ) support , standard doxorubicin/cisplatin chemotherapy produce improvement frequency objective response , progression-free survival , overall survival patient stage III , stage IV , recurrent endometrial carcinoma . - Compare toxicity two regimen patient . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive doxorubicin IV 15-30 minute , follow immediately cisplatin IV 1 hour . - Arm II : Patients receive doxorubicin cisplatin arm I day 1 . On day 2 , patient receive paclitaxel IV 3 hour . Patients also receive filgrastim ( G-CSF ) subcutaneously begin day 3 continue least 10 day . Courses repeat every 21 day . Treatment continue 7 course absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 240 patient ( 120 per arm ) accrue study within 21 month .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary stage III , stage IV , recurrent endometrial carcinoma Very poor potential cure radiotherapy surgery alone combination Measurable disease Disease irradiate field site measurable disease allow provide clear progression since completion radiotherapy PATIENT CHARACTERISTICS : Age 18 Performance status GOG 02 Life expectancy Not specify Hematopoietic Platelet count least 100,000/mm^3 Granulocyte count least 1,500/mm^3 Hepatic SGPT great 3 time upper limit normal Bilirubin normal Renal Creatinine great 1.6 mg/dL Cardiovascular LVEF least 50 % within past 6 month No uncontrolled angina No thirddegree complete heart block unless pacemaker place Neurologic No serious peripheral neuropathy Other No prior concurrent malignancy within past 5 year except nonmelanoma skin cancer No uncontrolled infection No sensitivity E. coliderived drug preparation PRIOR CONCURRENT THERAPY : Biologic therapy Prior biologic therapy allow No concurrent biologic therapy Chemotherapy No prior cytotoxic chemotherapy , include chemotherapy use radiation sensitization No prior chemotherapy prior malignancy Endocrine therapy Prior hormone therapy allow No concurrent hormone therapy Radiotherapy At least 4 week since prior radiotherapy whole pelvis 50 % spine Surgery Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>stage III endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
</DOC>